This record was last updated August 9, 2022 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
STARflo is a novel suprachoroidal Glaucoma Drainage Device (GDD), bleb-free, exhibiting anti-fibrotic properties. Release of this CE Marked implant has been limited to leading Glaucoma Centers in Europe.
Protocol Amendment History
6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2016-07-06; most recent amendment 2022-08-08.
Status change: Recruiting → Active, Not Recruiting2019-11-14
Status change: Not Yet Recruiting → Recruiting2017-10-16